KR20110074995A - 숙주 방어의 합성 모사체 및 이의 용도 - Google Patents

숙주 방어의 합성 모사체 및 이의 용도 Download PDF

Info

Publication number
KR20110074995A
KR20110074995A KR1020117009356A KR20117009356A KR20110074995A KR 20110074995 A KR20110074995 A KR 20110074995A KR 1020117009356 A KR1020117009356 A KR 1020117009356A KR 20117009356 A KR20117009356 A KR 20117009356A KR 20110074995 A KR20110074995 A KR 20110074995A
Authority
KR
South Korea
Prior art keywords
compound
halo
independently
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117009356A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 에프 데그란도
다후이 뤼
리차드 더블유 스코트
용지앙 쑤
하이즈홍 탕
보제나 콜크작
Original Assignee
폴리메딕스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴리메딕스, 인코포레이티드 filed Critical 폴리메딕스, 인코포레이티드
Publication of KR20110074995A publication Critical patent/KR20110074995A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020117009356A 2008-10-27 2009-10-27 숙주 방어의 합성 모사체 및 이의 용도 Ceased KR20110074995A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10859508P 2008-10-27 2008-10-27
US61/108,595 2008-10-27
US12/605,584 2009-10-26
US12/605,584 US8278309B2 (en) 2008-10-27 2009-10-26 Synthetic mimetics of host defense and uses thereof

Publications (1)

Publication Number Publication Date
KR20110074995A true KR20110074995A (ko) 2011-07-05

Family

ID=42118100

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117009356A Ceased KR20110074995A (ko) 2008-10-27 2009-10-27 숙주 방어의 합성 모사체 및 이의 용도

Country Status (14)

Country Link
US (2) US8278309B2 (enExample)
EP (1) EP2358380A4 (enExample)
JP (1) JP2012506908A (enExample)
KR (1) KR20110074995A (enExample)
CN (1) CN102256614B (enExample)
AU (1) AU2009320139B2 (enExample)
BR (1) BRPI0920251A2 (enExample)
CA (1) CA2741764A1 (enExample)
IL (1) IL212275A0 (enExample)
MX (1) MX2011004360A (enExample)
RU (1) RU2540077C2 (enExample)
TW (1) TWI478915B (enExample)
UA (1) UA104875C2 (enExample)
WO (1) WO2010062573A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
US8278309B2 (en) * 2008-10-27 2012-10-02 Polymedix, Inc. Synthetic mimetics of host defense and uses thereof
RU2606128C2 (ru) 2011-05-16 2017-01-10 Селлсьютикс Корпорейшн Соединения для применения в лечении мукозита
US9758607B2 (en) 2013-10-10 2017-09-12 Research Foundation Of The City University Of New York Polymer with antibacterial activity
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
CN107574581B (zh) * 2017-08-03 2019-09-10 天津大学 一种抗菌性聚(ε-己内酯)/模拟抗菌肽电纺纤维膜及其制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) * 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
CA2128612C (en) * 1992-01-23 1999-06-15 Mamoru Tomita Antimicrobial agents and method for treating products therewith
WO2000010990A2 (en) * 1998-08-20 2000-03-02 University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) * 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
ES2311035T3 (es) * 2000-11-08 2009-02-01 Fxs Ventures, Llc Soluciones oftalmicas y para lentes de contacto mejoradas que contienen formas de vitamina b.
EP1372551B1 (en) 2001-03-08 2008-09-17 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers as anti-infective agents
AU2002346457A1 (en) 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Pharmaceutical formulations comprising indolinone derivatives
CA2487454A1 (en) * 2002-05-28 2003-12-04 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
CA2489378A1 (en) * 2002-06-13 2003-12-24 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for simulating biomembranes using coarse grain models
WO2004082634A2 (en) * 2003-03-17 2004-09-30 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
AU2003249114A1 (en) 2003-03-20 2004-10-11 Shiseido International France Cosmetic composition
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
CA2554163A1 (en) 2004-01-23 2005-08-11 The Trustees Of The University Of Pennsylvania Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
JP2007534693A (ja) 2004-04-23 2007-11-29 サイデックス・インコーポレイテッド スルホアルキルエーテルシクロデキストリンを含有するｄｐｉ製剤
CN102653515A (zh) 2004-06-15 2012-09-05 宝利麦迪克斯股份有限公司 聚阳离子化合物及其用途
WO2006132647A2 (en) 2004-07-23 2006-12-14 The Trustees Of The University Of Pennsylvania Antimicrobial copolymers and uses thereof
EP2486942B1 (en) 2004-11-24 2018-10-10 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP2008524318A (ja) * 2004-12-21 2008-07-10 ファイザー・プロダクツ・インク 安定なアジスロマイシン非二水和物の経口用懸濁液剤
KR20080004475A (ko) 2005-02-25 2008-01-09 유니버시티 오브 매사추세츠 표면적으로 양친매성인 중합체 및 올리고머, 그 조성물 및암치료방법으로서의 그 용도
RU2325151C2 (ru) * 2006-06-29 2008-05-27 ООО "Научно-производственный центр "Амфион" Способ получения системы доставки водонерастворимых и плохорастворимых биологически активных веществ и лекарственная форма на ее основе
JP2008137978A (ja) * 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
JP2011529502A (ja) * 2008-07-28 2011-12-08 ポリメディックス・インコーポレーテッド 抗マラリア化合物
US8278309B2 (en) * 2008-10-27 2012-10-02 Polymedix, Inc. Synthetic mimetics of host defense and uses thereof

Also Published As

Publication number Publication date
UA104875C2 (uk) 2014-03-25
MX2011004360A (es) 2011-08-12
US20130090345A1 (en) 2013-04-11
US20100105703A1 (en) 2010-04-29
RU2540077C2 (ru) 2015-01-27
US8278309B2 (en) 2012-10-02
CN102256614A (zh) 2011-11-23
CN102256614B (zh) 2014-01-08
IL212275A0 (en) 2011-06-30
AU2009320139B2 (en) 2013-07-25
US8975262B2 (en) 2015-03-10
AU2009320139A1 (en) 2010-06-03
TW201020249A (en) 2010-06-01
BRPI0920251A2 (pt) 2016-01-05
EP2358380A1 (en) 2011-08-24
CA2741764A1 (en) 2010-06-03
JP2012506908A (ja) 2012-03-22
EP2358380A4 (en) 2012-05-02
RU2011121354A (ru) 2012-12-10
TWI478915B (zh) 2015-04-01
WO2010062573A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
KR20110074995A (ko) 숙주 방어의 합성 모사체 및 이의 용도
RU2636147C1 (ru) Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
RU2569307C1 (ru) Азотсодержащие соединения и их применение
CZ290445B6 (cs) Urethany a močoviny, způsoby jejich přípravy a farmaceutické přípravky na jejich bázi
EP2413974A1 (en) Conjugated antimicrobial agents
US6841661B2 (en) Glycopeptide antibacterial compounds, compositions containing same and methods of using same
US10919851B2 (en) 2-pyrrolidine phenylhydrazides antibacterial agents
WO2017186110A1 (zh) 一类万古霉素衍生物、其制备方法、药物组合物和用途
Singh et al. Synthesis and in vitro antibacterial activity of N-alkyl and N-aryl piperazine derivatives
US20020045574A1 (en) Glycopeptide antibacterial compounds and methods of using same
US11225465B2 (en) Albicidin derivatives, their use and synthesis
US20110015119A1 (en) Novel semi-synthetic glycopeptides as antibacterial agents
WO2016027262A1 (en) Antibacterial sideromycins
Kawakami et al. Studies on 8-methoxyquinolones: synthesis and antibacterial activity of 7-(3-amino-4-substituted) pyrrolidinyl derivatives
US9862680B2 (en) Peripherally substituted monocyclic beta-lactams
US20080132500A1 (en) Antibiotic compounds
JP2020055749A (ja) 多剤耐性菌に有効な新規アミノグリコシド抗生物質
KR102354697B1 (ko) 항박테리아 화합물로서의 헤테로고리 유도체
WO2007127135A2 (en) Antibiotic compounds
EP1712554A1 (en) Pyridobenzoxazine derivative
KR101264903B1 (ko) 2-피롤리돈기를 포함하는 옥사졸리디논 유도체 또는 이의 약학적으로 허용 가능한 염 및 이들의 제조방법
WO2014195697A1 (en) Novel pyrrole derivative
KR20160072152A (ko) 질소 함유 화합물 및 이들의 용도
NZ612912B2 (en) Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110425

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141016

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151218

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160427

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151218

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I